The stock of InflaRx N.V. (NASDAQ:IFRX) reached all time high today, Apr, 24 and still has $53.35 target or 3.00% above today’s $51.80 share price. This indicates more upside for the $1.35 billion company. This technical setup was reported by Barchart.com. If the $53.35 PT is reached, the company will be worth $40.35M more. The stock increased 0.37% or $0.19 during the last trading session, reaching $51.8. About 196,853 shares traded. InflaRx N.V. (NASDAQ:IFRX) has risen 39.39% since April 24, 2018 and is uptrending. It has outperformed by 35.02% the S&P500. Some Historical IFRX News: 17/05/2018 – InflaRx 1Q Loss/Shr EUR0.04; 29/03/2018 – InflaRx FY Loss/Shr EUR2.6; 17/05/2018 – InflaRx 1Q Loss EUR10.3M; 03/05/2018 – INFLARX PRIMARY, SECONDARY OFFERINGS PRICES AT $34.00 PER SHARE; 29/03/2018 – InflaRx Full Year 2017 Financial & Operating Results; 17/05/2018 – INFLARX NV – CASH POSITION APPROXIMATELY US$137 MLN (EUR 115 MLN) AS OF MARCH 31, 2018; 29/03/2018 – lnflaRx Full Year 2017 Financial & Operating Results; 08/05/2018 – INFLARX N.V. REPORTS CLOSING OF PRIMARY, SECONDARY OFFERING; 08/03/2018 InflaRx announces first patient enrolled in Phase IIb trial with lead candidate IFX-1 in Hidradenitis Suppurativa; 08/03/2018 – lnflaRx announces first patient enrolled in Phase llb trial with lead candidate IFX-1 in Hidradenitis Suppurativa
Nuvectra Corporation (NASDAQ:NVTR) had a decrease of 22.43% in short interest. NVTR’s SI was 503,400 shares in April as released by FINRA. Its down 22.43% from 649,000 shares previously. With 328,400 avg volume, 2 days are for Nuvectra Corporation (NASDAQ:NVTR)’s short sellers to cover NVTR’s short positions. The stock decreased 1.22% or $0.12 during the last trading session, reaching $9.75. About 12,771 shares traded. Nuvectra Corporation (NASDAQ:NVTR) has risen 21.49% since April 24, 2018 and is uptrending. It has outperformed by 17.12% the S&P500. Some Historical NVTR News: 11/05/2018 – Russell Investments Group Buys New 1.5% Position in Nuvectra; 10/04/2018 – Nuvectra Forms Golden Cross: Technicals; 08/03/2018 – Soin Neuroscience commences a clinical case series with Nuvectra’s Algovita spinal cord stimulator for back pain; 14/05/2018 – RTW Investments Buys New 3.6% Position in Nuvectra; 05/04/2018 – Nuvectra at Group Dinner Hosted By JMP Securities Today; 14/05/2018 – Next Century Growth Investors Buys New 1% Position in Nuvectra; 15/05/2018 – Driehaus Capital Management Buys New 2.5% Position in Nuvectra; 29/03/2018 – Nuvectra Group Dinner Scheduled By JMP Securities for Apr. 5; 02/05/2018 – Nuvectra 1Q Loss/Shr 84c; 23/04/2018 – DJ Nuvectra Corp, Inst Holders, 1Q 2018 (NVTR)
More notable recent InflaRx N.V. (NASDAQ:IFRX) news were published by: Streetinsider.com which released: “Inflarx NV (IFRX) PT Raised to $64 at BMO Capital Following Positive Physician Feedback – StreetInsider.com” on April 24, 2019, also Globenewswire.com with their article: “InflaRx Full Year 2018 Financial & Operating Results – GlobeNewswire” published on March 28, 2019, Nasdaq.com published: “InflaRx (IFRX) Catches Eye: Stock Jumps 7.5% – Nasdaq” on April 10, 2019. More interesting news about InflaRx N.V. (NASDAQ:IFRX) were released by: Benzinga.com and their article: “38 Stocks Moving In Tuesday’s Mid-Day Session – Benzinga” published on April 09, 2019 as well as Benzinga.com‘s news article titled: “46 Biggest Movers From Yesterday – Benzinga” with publication date: April 10, 2019.
InflaRx GmbH, a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology in the United States. The company has market cap of $1.35 billion. The Company’s C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. It currently has negative earnings. The firm is involved developing IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and other chronic/autoimmune diseases, as well as IFX-2 for the treatment of chronic inflammation and autoimmune diseases.